Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection

Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection is a highly advanced, specialized formulation of the anthracycline antibiotic doxorubicin, designed to improve the therapeutic index of cancer treatment. Unlike conventional chemotherapy, Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection utilizes “stealth” technology where the active drug is encapsulated within microscopic fat spheres called liposomes. These liposomes are coated with methoxypolyethylene glycol (MPEG), a process known as pegylation. This protective coating prevents the body’s immune system from detecting and destroying the drug prematurely, significantly extending its circulation time in the bloodstream. This prolonged circulation allows Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection to utilize the Enhanced Permeability and Retention (EPR) effect, where the drug passively accumulates in tumor tissues through their leaky blood vessels. Discover how this powerful treatment provides the ultimate targeted attack on malignancies while protecting healthy tissues, such as the heart, from excessive exposure.

Indications / Uses of Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection

Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection is commonly prescribed for the specialized management of:

• Ovarian Cancer: It is a primary treatment option for women with ovarian cancer whose disease has recurred or progressed after platinum-based chemotherapy. The pegylated formulation offers effective relief by maintaining therapeutic drug levels in the tumor for extended periods.
• Metastatic Breast Cancer: Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection is indicated for the treatment of metastatic breast cancer, particularly in patients where there is a significant cardiac risk with traditional anthracyclines. It is often used as a single agent or in combination with other chemotherapeutics.
• AIDS-Related Kaposi’s Sarcoma: This medication is widely considered a first-line therapy for patients with AIDS-related Kaposi’s sarcoma, providing a powerful cytotoxic effect against the extensive skin and visceral lesions associated with the disease.
• Multiple Myeloma: In combination with bortezomib, Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection acts as a potent anti-myeloma agent for patients who have received at least one prior therapy.

Key Features

• Reduced Cardiotoxicity: The most distinct feature of Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection is its safety profile; the liposomal encapsulation prevents the drug from being released in high concentrations in the heart muscle, significantly lowering the risk of irreversible heart damage compared to standard doxorubicin.
• Targeted “Stealth” Delivery: The pegylated coating hides the liposome from the mononuclear phagocyte system (immune defense), allowing the medication to circulate for days rather than minutes, increasing the likelihood of it reaching the tumor site.
• Sustained Release Profile: Once accumulated in the tumor tissue, the liposomes slowly break down, releasing Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection directly into the cancer cells over time, ensuring a durable cytotoxic effect.
• Convenient Dosing Schedule: Due to its long half-life, this formulation is typically administered less frequently than standard chemotherapy, often every 4 weeks, improving patient compliance and comfort.

Storage for Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection

To preserve the integrity of the delicate liposomal structure, Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection must be stored under strict refrigeration between 2°C and 8°C (36°F to 46°F). Do not freeze the vials, as freezing can rupture the liposomes and destroy the controlled-release mechanism. The medication should be kept in its original carton to protect it from light until the time of use. Any unused portion must be discarded immediately, as the product does not contain preservatives.

Important Note on Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection

Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection requires administration by a qualified oncology professional via intravenous infusion. It must not be administered as a bolus injection or undiluted. One of the unique side effects of this liposomal formulation is Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome), characterized by redness, swelling, and peeling of the skin on the palms and soles. Patients should avoid tight-fitting footwear and exposure to heat (like hot water) to minimize this risk.

While Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection has reduced cardiotoxicity, heart function monitoring (LVEF) is still mandatory before and during treatment. Infusion-related reactions, which may resemble allergic reactions (flushing, shortness of breath, chest tightness), can occur, typically during the first infusion; slowing the infusion rate often resolves these symptoms. The medication causes reddish discoloration of urine, which is not blood but the drug being excreted. Severe myelosuppression (anemia, neutropenia, thrombocytopenia) can occur, so regular blood counts are essential. By strictly following these professional guidelines, Doxorubin Hydrochloride Pegylated Liposomal 20mg/10ml Injection provides a powerful and safer alternative for long-term cancer management.